HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has reached a pivotal milestone by dosing its first patient in the U.S. for the NEXICART-2 clinical trial. This significant achievement aims to treat relapsed/refractory AL Amyloidosis using CAR-T cell therapy, known as NXC-201.
The biopharmaceutical industry is witnessing major advancements in cell therapy, with CAR-T therapies surfacing as a pioneering avenue for treating complex diseases. The latest development in this field is the expanded strategic collaboration between IASO Biotechnology (IASO Bio) and Innovent
Clinical trial outsourcing has fundamentally transformed the landscape of drug development, allowing pharmaceutical companies to streamline operations, reduce costs, and accelerate the path to market. This paradigm shift is driven by several converging factors, including the rapid growth in
The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown
In recent years, the intersection of advanced computing and biological research has elevated the prospects of drug discovery to unprecedented heights. The seamless integration of AI, machine learning, and supercomputing promises a paradigmatic shift from traditional empiricism to computational
